vimarsana.com
Home
Live Updates
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 ... : vimarsana.com
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 ... : vimarsana.com
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 ...
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660; expect to initiate tumor-specific expansion cohorts in the second quarter of 2024 and announce initial
Related Keywords
Germany ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Spain ,
Barcelona ,
Comunidad Autonoma De Cataluna ,
Martin Huber ,
Immunosynthen Adcs ,
Jason Fredette ,
Dolasynthen Adcs ,
Merck Kga ,
Drug Administration ,
Nasdaq ,
Johnson ,
Mersana Therapeutics Inc ,
Exchange Commission ,
Merck Kgaa ,
European Society Of Gynaecological Oncology ,
Chief Executive Officer ,
Strategic Priorities ,
Upcoming Data Presentations ,
European Society ,
Gynaecological Oncology ,
Private Securities Litigation Reform Act ,
Quarterly Report ,
Consolidated Statement ,